肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

ESMO 2020：EPI-7386治疗前列腺癌的临床前数据，取得积极结果

2020-09-18 Allan MedSci原创

前列腺癌转移性前列腺癌患者EPI-7386
关注

前列腺癌是男性第二大常见癌症，也是全球男性第五大癌症死亡原因。前列腺癌依赖于雄激素来促进肿瘤进展，消耗或阻断雄激素的激素疗法是治疗前列腺癌主要手段。尽管肿瘤最初对降低睾丸激素水平的药物或手术疗法敏感，

前列腺癌是男性第二大常见癌症，也是全球男性第五大癌症死亡原因。前列腺癌依赖于雄激素来促进肿瘤进展，消耗或阻断雄激素的激素疗法是治疗前列腺癌主要手段。尽管肿瘤最初对降低睾丸激素水平的药物或手术疗法敏感，但疾病进展通常是致命的。在过去的五年中，尽管转移性前列腺癌（mCRPC）患者的治疗手段取得了多项进步，但仍需要其他治疗方案来改善患者的临床结局，特别是那些在现有治疗中失败的患者或有禁忌症的患者。

ESSA Pharma是一家临床阶段的制药公司，致力于开发治疗前列腺癌的新型疗法，ESSA Pharma近日宣布，在2020年ESMO虚拟大会上公布的EPI-7386临床前数据取得了积极结果。

EPI-7386是一款第二代N末端域雄激素受体抑制，在体外VCaP模型中，将EPI-7386与enzalutamide，apalutamide或darolutamide的组合治疗比单独使用每种单一药剂对AR相关转录活性的抑制作用更广、更深。

ESSA Pharma总裁兼首席执行官David R. Parkinson说：“这些数据为研究EPI-7386治疗前列腺癌的有效性提供了有力证据”。

 

原始出处：

https://www.firstwordpharma.com/node/1758552?tsid=4

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003462, encodeId=d26c2003462b4, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Sun Dec 06 08:15:47 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024894, encodeId=3f48202489436, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Feb 28 22:15:47 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797309, encodeId=3e121e9730971, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Mar 15 09:15:47 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281037, encodeId=49fd128103e6f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sun Sep 20 08:15:47 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040841, encodeId=8b731040841a2, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 18 20:15:47 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-12-06 fengxx

    #EPI-7386#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2003462, encodeId=d26c2003462b4, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Sun Dec 06 08:15:47 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024894, encodeId=3f48202489436, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Feb 28 22:15:47 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797309, encodeId=3e121e9730971, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Mar 15 09:15:47 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281037, encodeId=49fd128103e6f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sun Sep 20 08:15:47 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040841, encodeId=8b731040841a2, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 18 20:15:47 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2021-02-28 liuhuangbo

    #SMO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2003462, encodeId=d26c2003462b4, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Sun Dec 06 08:15:47 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024894, encodeId=3f48202489436, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Feb 28 22:15:47 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797309, encodeId=3e121e9730971, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Mar 15 09:15:47 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281037, encodeId=49fd128103e6f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sun Sep 20 08:15:47 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040841, encodeId=8b731040841a2, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 18 20:15:47 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2021-03-15 cqlidoudou

    #临床前数据#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2003462, encodeId=d26c2003462b4, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Sun Dec 06 08:15:47 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024894, encodeId=3f48202489436, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Feb 28 22:15:47 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797309, encodeId=3e121e9730971, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Mar 15 09:15:47 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281037, encodeId=49fd128103e6f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sun Sep 20 08:15:47 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040841, encodeId=8b731040841a2, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 18 20:15:47 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-09-20 zhang92560

    #ESMO#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2003462, encodeId=d26c2003462b4, content=<a href='/topic/show?id=901268e007' target=_blank style='color:#2F92EE;'>#EPI-7386#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6870, encryptionId=901268e007, topicName=EPI-7386)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Sun Dec 06 08:15:47 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024894, encodeId=3f48202489436, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Feb 28 22:15:47 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797309, encodeId=3e121e9730971, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Mar 15 09:15:47 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281037, encodeId=49fd128103e6f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sun Sep 20 08:15:47 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040841, encodeId=8b731040841a2, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 18 20:15:47 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-09-18 misszhang

    前列腺癌相关研究，学习了，谢谢梅斯

    0

相关资讯

Br J Cancer：EGFR—前列腺癌骨转移的稳定标志物

前列腺癌（PCa）是全世界男性中最常见的恶性肿瘤之一。尽管局部PCa患者的5年生存率接近100％，但转移性前列腺癌仍然无法治愈。因此，迫切需要相关的标记物来检测监测肿瘤转移的初始阶段、肿瘤复发的可能性

Nat Genet：前列腺癌中LSD1介导的甲基化能够促进FOXA1的染色质结合

FOXA1作为一个先锋转录因子，能够促进类固醇激素受体与染色质的结合，比如雄激素受体和雌激素受体，但是调控这些受体结合到染色质的机制仍旧不清楚。

J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化

目前人们对病人的治疗反应异质性仍然认识不足。使用18F-NaF正电子发射断层扫描/计算机断层扫描(PET/CT)的定量全骨成像(QTBI)是一种工具，它可用于描述骨内间治疗反应异质性。理解空间-时间反

Prostate Cancer P D：未治疗转移前列腺癌前期化疗的生存率研究

基于临床试验数据，前期化疗可延长转移性、激素敏感性前列腺癌（mHSPC）男性的总生存。最近，有研究人员在一个真实世界的队列中评估了前期化疗与mHSPC男性总生存之间的关联。

Cancer：接受根治性前列腺切除术后的前列腺癌死亡率的种族差异

尽管前列腺癌生存率的种族差异已被详细的记录，但导致差异的各种因素的相对重要性人们仍不清楚。也少有研究考察白人与西班牙裔、白人与亚裔美国人和太平洋岛民(AAPIs)之间的差异。

Am J Clin Nutr：随访长达11年，长期大量摄入乳制品或者是钙，前列腺癌风险增加至少30%

高钙摄入量（主要来自乳制品）可能会通过降低1，25-二羟基维生素D3 [1，25（OH）2D3]（一种被认为可预防前列腺癌的激素）的浓度而增加前列腺癌的风险。该假说的流行病学研究结果尚无定论。

拓展阅读

论文解读 | 平浩教授团队利用空间转录组学揭示前列腺癌进展的驱动基因

该研究利用空间转录组学精准描绘前列腺癌的分子演进图谱，定位驱动恶性进展的关键基因，为理解疾病分子机制提供新视角，也为未来精准诊断与治疗带来新希望。

NEJM：3 年无进展生存率提升 21%！PARP抑制剂改写 HRR 突变前列腺癌一线治疗格局

TALAPRO-3 研究在非 BRCA 突变亚组中显示出更显著的获益，进一步证实了全面 HRR 基因检测在转移性 APMS 前列腺癌患者中的重要性。

ASCO 2026：由Decipher基因组分类器驱动的 NCCN 风险重分类，以追踪早期前列腺癌中独特的转录组特征

由基因组分类器驱动的 NCCN 风险重分类与超越临床病理分层的一致性转录组模式密切相关。

PSA正常，肿瘤却悄悄扩散？”JCO重磅：患者正被这个指标“欺骗

本研究为晚期前列腺癌的临床监测策略敲响了警钟。在恩扎卢胺时代，PSA作为单一监测指标已不可靠。

Lancet Oncol：血清前列腺特异性抗原联合转移负荷精准预测前列腺癌 8 年生存

该研究还首次验证了在接受 ARPI 治疗的极高危非转移性前列腺癌患者中，治疗后 PSA 的预后价值。研究结果为临床实践提供了实用的生存预测工具，同时也为个体化治疗决策提供了依据。

NEJM：潮热更少、骨质更稳，经皮雌二醇贴片挑战前列腺癌标准治疗

经皮雌二醇贴片用于局部晚期前列腺癌患者，在 3 年无转移生存方面非劣于标准 LHRH 激动剂，且潮热更少、骨健康更佳、无注射负担，仅男性乳房发育风险升高。